Videos

Roman Drai, MD, PhD, deputy director and head of clinical operations at Geropharm, discussed Geropharm’s budding biosimilar pipeline and the company’s international pursuits during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Jim Koeller, a professor of pharmacotherapy and member of the Center for Pharmacoeconomic Studies in the College of Pharmacy at the University of Texas at Austin, discusses how payers influence biosimilar prescriptions and the pressure to lower drug costs for patients.

Ted Mathias and Stacie Ropka, PhD, both patent attorneys and partners at Axinn, Veltrop and Harkrider LLP, discuss patent exclusivity for biological drugs and other important issues that need to be addressed whether or not the ACA and the Biologics Price Competition and Innovation Act (BPCIA) are ruled invalid.

Here are the top 5 biosimilars articles for the week of May 4, 2020.

Ted Mathias and Stacie Ropka, PhD, patent attorneys and partners at Axinn, Veltrop, and Harkrider LLP, discuss past and future court decisions that leave the Affordable Care Act (ACA) in jeopardy and what could happen to the Biologics Price Competition and Innovation Act (BPCIA) as a result.

Molly Burich, MS, head of public policy at Boehringer Ingelheim, discusses several tactics that would help increase biosimilar uptake in the United States and get around current obstacles during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Ted Mathias and Stacie Ropka, PhD, patent attorneys and partners at Axinn, Veltrop, and Harkrider LLP, discuss the overall pushback to the Affordable Care Act (ACA) and what that means for the Biologics Price Competition and Innovation Act (BPCIA).

Here are the top 5 biosimilars articles for the week of April 27, 2020.

Christine Simmon talks about whether or not biosimilar uptake will happen as rapidly as it did for generics at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.

Two IPD Analytics pharmacy experts discuss the ever-growing number of Humira (adalimumab) biosimilars, how developers are trying to stand out from the crowd, and the potential for the first-ever interchangeable biosimilar.

Two IPD Analytics pharmacy experts give us their take on the overall biosimilar pipeline, but also on how incoming insulin products are positioned for success.

Here are the top 5 biosimilars articles for the week of April 20, 2020.

Molly Burich, MS, head of public policy at Boehringer Ingelheim (BI), discusses how the FDA's new guidance on interchangeability designation will improve confidence and acceptance for biosimilars during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Molly Burich, MS, head of public policy at Boehringer Ingelheim, discusses the why there currently are no biosimilars with an interchangeability designation during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California..

Will Gatziolis, MBA, an associate principal at ZS, talks how the coronavirus (COVID-19) pandemic will help biosimilar uptake and what manufacturers can do to take advantage of this opportunity.

Ruby Singh, vice president for Education and Training, Academy of Managed Care Pharmacy (AMCP), speaks with Mary Caffrey about the upcoming AMCP eLearning Days, a virtual meeting that will take place April 20 to 24. AMCP's annual meeting was canceled due to coronavirus disease 2019 (COVID-19). This transcript is edited slightly for clarity.

Here are the top 5 biosimilars articles for the week of April 13, 2020.

Surya Singh, MD discusses how education efforts have reduced providers’ doubts surrounding the similarity between biosimilars and their reference products at the March 2020 FDA/Federal Trade Commission workshop on anticompetitive practices.

Sarfaraz Niazi, PhD, an adjunct professor of biopharmaceutical Sciences at the College of Pharmacy at the University of Illinois at Chicago, discusses how the COVID-19 (coronavirus) pandemic is affecting drug shortages, challenging the FDA, and creating an greater opportunity for biosimilars down the road.

The Center for Biosimilars® recaps the top stories for the week of April 6, 2020.

Surya Singh, MD, discussed dynamics that affect biosimilar uptake on the medical benefits side and how that differs from the pharmacy benefits side at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.

Soumi Saha, PharmD, JD, senior director of advocacy at Premier, Inc, discusses drug shortages caused by coronavirus disease (COVID-19) and policy recommendations that could fix the problem.

The Center for Biosimilars® recaps the top stories for the week of March 30, 2020.

Christine Simmon discussed the Purple Book and how it will affect biosimilar makers and illuminate patent hurdles at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.

Matt Harman talks about what employers can do to help promote biosimilar adoption in the United States, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

The Center for Biosimilars® recaps the top stories for the week of March 23, 2020.

Matt Harman talks about employer interest in biosimilar promotion and how the FDA's new biologics pathway change will affect interest levels, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Wayne Winegarden, PhD, talked about the issues and benefits of the FDA's switch to a biologics regulatory pathway for certain products, especially insulin, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Sheila Frame, the vice president of marketing, market access, and patient services at Sandoz, discusses US biosimilar policies in development and the impact they will have on the market at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.

Wayne Winegarden, PhD discusses the potential savings inherent in biosimilars at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.